Collegium Pharmaceutical Inc (NASDAQ:COLL) – Analysts at Gabelli lowered their FY2018 EPS estimates for shares of Collegium Pharmaceutical in a research report issued to clients and investors on Tuesday, January 8th. Gabelli analyst K. Kedra now forecasts that the specialty pharmaceutical company will post earnings of ($1.85) per share for the year, down from their prior estimate of ($1.80). Gabelli also issued estimates for Collegium Pharmaceutical’s FY2019 earnings at ($0.05) EPS, FY2020 earnings at $0.45 EPS and FY2021 earnings at $1.00 EPS.
Several other brokerages also recently commented on COLL. ValuEngine raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday, November 13th. Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research note on Wednesday. BidaskClub raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. HC Wainwright reissued a “buy” rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $30.43.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.14). The company had revenue of $70.20 million for the quarter, compared to analyst estimates of $74.79 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The firm’s quarterly revenue was up 485.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.45) earnings per share.
Institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Collegium Pharmaceutical in the 2nd quarter valued at about $213,000. Atria Investments LLC increased its position in Collegium Pharmaceutical by 81.3% in the 3rd quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock valued at $226,000 after buying an additional 6,866 shares in the last quarter. Jefferies Group LLC bought a new stake in Collegium Pharmaceutical in the 3rd quarter valued at about $271,000. Capital Fund Management S.A. bought a new stake in Collegium Pharmaceutical in the 3rd quarter valued at about $286,000. Finally, Man Group plc bought a new stake in Collegium Pharmaceutical in the 3rd quarter valued at about $287,000.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $16.60, for a total value of $415,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 75,000 shares of company stock worth $1,282,750 over the last three months. 13.87% of the stock is owned by company insiders.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.